U.S., Aug. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07098052) titled 'A Study of HDM2020 in Patients With Advanced Solid Tumors' on July 18.
Brief Summary: The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are:
* Is the drug safe and tolerable ?
* Does the drug exhibit antitumor activity ?
Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.
Study Start Date: Aug. 11
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
DRUG: HDM2020
FGFR2b-ADC
Recruitment Status: RECRUITING
Sponsor: Hangzhou Zhongmei Huadong P...